Last reviewed · How we verify
4P004
4P004 is a small molecule that targets the [unknown molecular target] to treat [unknown therapeutic area].
At a glance
| Generic name | 4P004 |
|---|---|
| Also known as | Liraglutide |
| Sponsor | 4Moving Biotech |
| Modality | Small molecule |
| Phase | Phase 2 |
Mechanism of action
Further research is needed to understand the exact mechanism of action of 4P004.
Approved indications
Common side effects
Key clinical trials
- A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis (PHASE2)
- Safety, Tolerability and Pharmacokinetics of Intraarticular 4P004 Single Dose in Patient With KL 2-4 Osteoarthritic Knee (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 4P004 CI brief — competitive landscape report
- 4P004 updates RSS · CI watch RSS
- 4Moving Biotech portfolio CI